Overexpression of extracellular matrix metalloproteinase inducer in multidrug resistant cancer cells

Jin Ming Yang, Zude Xu, Hao Wu, Hongguang Zhu, Xiaohua Wu, William N. Hait

Research output: Contribution to journalArticle

174 Citations (Scopus)

Abstract

Multidrug resistant (MDR) cancer cells overexpressing P-glycoprotein (P-gp) display variations in invasive and metastatic behavior. We previously reported that these properties of MDR cancer cell lines overexpressing P-gp could be altered by chemotherapeutic drugs or MDR modulators (R. S. Kerbel et aL, Cancer Surv., 7-: 597-629, 1988). To attempt to clarify the mechanism(s) underlying these observations, we studied the expression of extracellular matrix metalloproteinase inducer (EMMPRIN), a glycoprotein enriched on the surface of tumor cells that can stimulate the production of matrix metalloproteinases MDR cancer cells. Using immunofluorescence staining and fluorescence-activated cell sorting analysis, we found that EMMPRIN expression was increased in MDR carcinoma cell lines, MCF-7/AdrR, KBV-1, and A2780Dx5, as compared to their parental counterparts. The MDR cell lines produced more matrix metalloproteinase-1 (MMP-1), matrix metalloproteinase-2 (MMP-2), and matrix metalloproteinase-9 (MMP-9), as determined by zymography, Western blot, and reverse transcription-PCR. Treatment of MDR cells with an anti-EMMPRIN antibody inhibited the activity of MMP-1, MMP-2, and MMP-9. In MDR cell line MCF-7/AdrR, an increased in vitro invasive ability was observed as compared with the sensitive line MCF-7, and EMMPRIN antibody could inhibit the in vitro invasion in drug-resistant cells. In addition, the expression and activity of MMP-1, MMP-2, and MMP-9 in MDR cells were decreased by treatment with U-0126, an inhibitor of mitogen-activated protein kinase/extracellular signal regulated kinase (MAPK/Erk). Our results suggest that during the development of MDR, the expression of EMMPRIN is responsible for the increased activity of MMP in MDR cell lines.

Original languageEnglish (US)
Pages (from-to)420-427
Number of pages8
JournalMolecular Cancer Research
Volume1
Issue number6
StatePublished - Apr 1 2003

Fingerprint

CD147 Antigens
Matrix Metalloproteinase 1
Matrix Metalloproteinase 2
Matrix Metalloproteinase 9
Cell Line
Neoplasms
P-Glycoprotein
Matrix Metalloproteinases
Antibodies
Extracellular Signal-Regulated MAP Kinases
Mitogen-Activated Protein Kinases
Pharmaceutical Preparations
Reverse Transcription
Fluorescent Antibody Technique
Glycoproteins
Flow Cytometry
Western Blotting
Staining and Labeling
Carcinoma
Polymerase Chain Reaction

All Science Journal Classification (ASJC) codes

  • Molecular Biology
  • Oncology
  • Cancer Research

Cite this

Yang, J. M., Xu, Z., Wu, H., Zhu, H., Wu, X., & Hait, W. N. (2003). Overexpression of extracellular matrix metalloproteinase inducer in multidrug resistant cancer cells. Molecular Cancer Research, 1(6), 420-427.
Yang, Jin Ming ; Xu, Zude ; Wu, Hao ; Zhu, Hongguang ; Wu, Xiaohua ; Hait, William N. / Overexpression of extracellular matrix metalloproteinase inducer in multidrug resistant cancer cells. In: Molecular Cancer Research. 2003 ; Vol. 1, No. 6. pp. 420-427.
@article{39cd305eebdc47eea521e330dae1f7b7,
title = "Overexpression of extracellular matrix metalloproteinase inducer in multidrug resistant cancer cells",
abstract = "Multidrug resistant (MDR) cancer cells overexpressing P-glycoprotein (P-gp) display variations in invasive and metastatic behavior. We previously reported that these properties of MDR cancer cell lines overexpressing P-gp could be altered by chemotherapeutic drugs or MDR modulators (R. S. Kerbel et aL, Cancer Surv., 7-: 597-629, 1988). To attempt to clarify the mechanism(s) underlying these observations, we studied the expression of extracellular matrix metalloproteinase inducer (EMMPRIN), a glycoprotein enriched on the surface of tumor cells that can stimulate the production of matrix metalloproteinases MDR cancer cells. Using immunofluorescence staining and fluorescence-activated cell sorting analysis, we found that EMMPRIN expression was increased in MDR carcinoma cell lines, MCF-7/AdrR, KBV-1, and A2780Dx5, as compared to their parental counterparts. The MDR cell lines produced more matrix metalloproteinase-1 (MMP-1), matrix metalloproteinase-2 (MMP-2), and matrix metalloproteinase-9 (MMP-9), as determined by zymography, Western blot, and reverse transcription-PCR. Treatment of MDR cells with an anti-EMMPRIN antibody inhibited the activity of MMP-1, MMP-2, and MMP-9. In MDR cell line MCF-7/AdrR, an increased in vitro invasive ability was observed as compared with the sensitive line MCF-7, and EMMPRIN antibody could inhibit the in vitro invasion in drug-resistant cells. In addition, the expression and activity of MMP-1, MMP-2, and MMP-9 in MDR cells were decreased by treatment with U-0126, an inhibitor of mitogen-activated protein kinase/extracellular signal regulated kinase (MAPK/Erk). Our results suggest that during the development of MDR, the expression of EMMPRIN is responsible for the increased activity of MMP in MDR cell lines.",
author = "Yang, {Jin Ming} and Zude Xu and Hao Wu and Hongguang Zhu and Xiaohua Wu and Hait, {William N.}",
year = "2003",
month = "4",
day = "1",
language = "English (US)",
volume = "1",
pages = "420--427",
journal = "Molecular Cancer Research",
issn = "1541-7786",
publisher = "American Association for Cancer Research Inc.",
number = "6",

}

Yang, JM, Xu, Z, Wu, H, Zhu, H, Wu, X & Hait, WN 2003, 'Overexpression of extracellular matrix metalloproteinase inducer in multidrug resistant cancer cells', Molecular Cancer Research, vol. 1, no. 6, pp. 420-427.

Overexpression of extracellular matrix metalloproteinase inducer in multidrug resistant cancer cells. / Yang, Jin Ming; Xu, Zude; Wu, Hao; Zhu, Hongguang; Wu, Xiaohua; Hait, William N.

In: Molecular Cancer Research, Vol. 1, No. 6, 01.04.2003, p. 420-427.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Overexpression of extracellular matrix metalloproteinase inducer in multidrug resistant cancer cells

AU - Yang, Jin Ming

AU - Xu, Zude

AU - Wu, Hao

AU - Zhu, Hongguang

AU - Wu, Xiaohua

AU - Hait, William N.

PY - 2003/4/1

Y1 - 2003/4/1

N2 - Multidrug resistant (MDR) cancer cells overexpressing P-glycoprotein (P-gp) display variations in invasive and metastatic behavior. We previously reported that these properties of MDR cancer cell lines overexpressing P-gp could be altered by chemotherapeutic drugs or MDR modulators (R. S. Kerbel et aL, Cancer Surv., 7-: 597-629, 1988). To attempt to clarify the mechanism(s) underlying these observations, we studied the expression of extracellular matrix metalloproteinase inducer (EMMPRIN), a glycoprotein enriched on the surface of tumor cells that can stimulate the production of matrix metalloproteinases MDR cancer cells. Using immunofluorescence staining and fluorescence-activated cell sorting analysis, we found that EMMPRIN expression was increased in MDR carcinoma cell lines, MCF-7/AdrR, KBV-1, and A2780Dx5, as compared to their parental counterparts. The MDR cell lines produced more matrix metalloproteinase-1 (MMP-1), matrix metalloproteinase-2 (MMP-2), and matrix metalloproteinase-9 (MMP-9), as determined by zymography, Western blot, and reverse transcription-PCR. Treatment of MDR cells with an anti-EMMPRIN antibody inhibited the activity of MMP-1, MMP-2, and MMP-9. In MDR cell line MCF-7/AdrR, an increased in vitro invasive ability was observed as compared with the sensitive line MCF-7, and EMMPRIN antibody could inhibit the in vitro invasion in drug-resistant cells. In addition, the expression and activity of MMP-1, MMP-2, and MMP-9 in MDR cells were decreased by treatment with U-0126, an inhibitor of mitogen-activated protein kinase/extracellular signal regulated kinase (MAPK/Erk). Our results suggest that during the development of MDR, the expression of EMMPRIN is responsible for the increased activity of MMP in MDR cell lines.

AB - Multidrug resistant (MDR) cancer cells overexpressing P-glycoprotein (P-gp) display variations in invasive and metastatic behavior. We previously reported that these properties of MDR cancer cell lines overexpressing P-gp could be altered by chemotherapeutic drugs or MDR modulators (R. S. Kerbel et aL, Cancer Surv., 7-: 597-629, 1988). To attempt to clarify the mechanism(s) underlying these observations, we studied the expression of extracellular matrix metalloproteinase inducer (EMMPRIN), a glycoprotein enriched on the surface of tumor cells that can stimulate the production of matrix metalloproteinases MDR cancer cells. Using immunofluorescence staining and fluorescence-activated cell sorting analysis, we found that EMMPRIN expression was increased in MDR carcinoma cell lines, MCF-7/AdrR, KBV-1, and A2780Dx5, as compared to their parental counterparts. The MDR cell lines produced more matrix metalloproteinase-1 (MMP-1), matrix metalloproteinase-2 (MMP-2), and matrix metalloproteinase-9 (MMP-9), as determined by zymography, Western blot, and reverse transcription-PCR. Treatment of MDR cells with an anti-EMMPRIN antibody inhibited the activity of MMP-1, MMP-2, and MMP-9. In MDR cell line MCF-7/AdrR, an increased in vitro invasive ability was observed as compared with the sensitive line MCF-7, and EMMPRIN antibody could inhibit the in vitro invasion in drug-resistant cells. In addition, the expression and activity of MMP-1, MMP-2, and MMP-9 in MDR cells were decreased by treatment with U-0126, an inhibitor of mitogen-activated protein kinase/extracellular signal regulated kinase (MAPK/Erk). Our results suggest that during the development of MDR, the expression of EMMPRIN is responsible for the increased activity of MMP in MDR cell lines.

UR - http://www.scopus.com/inward/record.url?scp=0037392052&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037392052&partnerID=8YFLogxK

M3 - Article

C2 - 12692261

AN - SCOPUS:0037392052

VL - 1

SP - 420

EP - 427

JO - Molecular Cancer Research

JF - Molecular Cancer Research

SN - 1541-7786

IS - 6

ER -